GlaxoSmithKline Pakistan reports higher quarterly profit for the quarter ended September 30, 2026
Financial ResultGlaxoSmithKline Pakistan’s quarterly revenue, operating profit, profit after taxation and EPS all increased year on year. No cash dividend was recommended.
Payout
- No cash dividend
Key Findings
- Quarterly revenue increased to Rs. 16,594,106 thousand from Rs. 14,188,008 thousand.
- Quarterly operating profit rose to Rs. 4,160,588 thousand from Rs. 3,248,872 thousand.
- Quarterly profit after taxation increased to Rs. 2,610,463 thousand from Rs. 2,037,285 thousand; EPS rose to Rs. 8.20 from Rs. 6.40.
- The board recommended no cash dividend, bonus shares or right shares.
Financial Performance
| Metric | PreviousQuarter ended September 30, 2025 | CurrentQuarter ended September 30, 2026 | Change |
|---|---|---|---|
| Revenue from contracts with customers – net | PKR 14.19B | PKR 16.59B | +17% |
| Gross profit | PKR 5.21B | PKR 6.48B | +24.4% |
| Operating profit | PKR 3.25B | PKR 4.16B | +28.1% |
| Profit after taxation | PKR 2.04B | PKR 2.61B | +28.1% |
| Earnings per share | Rs. 6.40 | Rs. 8.20 | +28.1% |
| Financial (charges) / income | PKR 42.93M | -PKR 60.01M | -239.8% |
| Cash and bank balances | PKR 8.59B | PKR 8.15B | -5.2% |
⚡
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.


